Medtronic expands atrial fibrillation effort with equity stake in PharmaTarget.
This article was originally published in The Gray Sheet
Executive Summary
MEDTRONIC 9% EQUITY STAKE IN PHARMATARGET will allow the firm to monitor development of PharmaTarget's implantable pharmacologic atrioverter pump for atrial fibrillation therapy. Under an agreement announced in mid-December, Medtronic took a 9% position in the Minneapolis-based company for an undisclosed amount of cash. The investment also gives Medtronic VP-Corporate Technology Larry Shearon a seat on PharmaTarget's board.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.